Tags

Type your tag names separated by a space and hit enter

[Erysipelas after breast cancer treatment].
Tunis Med 2002; 80(8):465-8TM

Abstract

BACKGROUND

Study of the epidemiological, clinical and evolutive characteristics of the erysipelas of patients treated for breast cancer.

PATIENTS AND METHODS

Between February 93 and December 99, 20 patients among 700 (2.85%) treated for breast cancer in the radiotherapy department of sfax have presented an erysipelas. All of these patients had undergone a chirurgical treatment containing an axillary lymph node dissection with radiotherapy in 95% and adjuvent chemotherapy in 80% of cases.

RESULTS

The medium delay between the appearance of the eryslpelas and the end of treatment was 23 months. The preferential localisation was the homolateral upper limb to the treated breast (95%). The immediate evolution was favourable in 85% after antibiotherapy. Recurrence of erysipelas was seen in 20% in cases.

DISCUSSION

Erysipelas after treatment of breast cancer is known but rarely reported. The secondary lymphedema of the upper limb is the major favouring factor.

CONCLUSION

Appearance of erysipelas among women treated for breast cancer is frequent, his recurrent character must always lead to antibiotic prophylaxis.

Authors+Show Affiliations

Service de Radiothérapie Carcinologique, C.H.U. Habib Bourguiba Sfax.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

fre

PubMed ID

12703126

Citation

Ben Salah, H, et al. "[Erysipelas After Breast Cancer Treatment]." La Tunisie Medicale, vol. 80, no. 8, 2002, pp. 465-8.
Ben Salah H, Siala W, Maaloul I, et al. [Erysipelas after breast cancer treatment]. Tunis Med. 2002;80(8):465-8.
Ben Salah, H., Siala, W., Maaloul, I., Bouzid, F., Frikha, M., & Daoud, J. (2002). [Erysipelas after breast cancer treatment]. La Tunisie Medicale, 80(8), pp. 465-8.
Ben Salah H, et al. [Erysipelas After Breast Cancer Treatment]. Tunis Med. 2002;80(8):465-8. PubMed PMID: 12703126.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Erysipelas after breast cancer treatment]. AU - Ben Salah,H, AU - Siala,W, AU - Maaloul,I, AU - Bouzid,F, AU - Frikha,M, AU - Daoud,J, PY - 2003/4/22/pubmed PY - 2003/6/7/medline PY - 2003/4/22/entrez SP - 465 EP - 8 JF - La Tunisie medicale JO - Tunis Med VL - 80 IS - 8 N2 - BACKGROUND: Study of the epidemiological, clinical and evolutive characteristics of the erysipelas of patients treated for breast cancer. PATIENTS AND METHODS: Between February 93 and December 99, 20 patients among 700 (2.85%) treated for breast cancer in the radiotherapy department of sfax have presented an erysipelas. All of these patients had undergone a chirurgical treatment containing an axillary lymph node dissection with radiotherapy in 95% and adjuvent chemotherapy in 80% of cases. RESULTS: The medium delay between the appearance of the eryslpelas and the end of treatment was 23 months. The preferential localisation was the homolateral upper limb to the treated breast (95%). The immediate evolution was favourable in 85% after antibiotherapy. Recurrence of erysipelas was seen in 20% in cases. DISCUSSION: Erysipelas after treatment of breast cancer is known but rarely reported. The secondary lymphedema of the upper limb is the major favouring factor. CONCLUSION: Appearance of erysipelas among women treated for breast cancer is frequent, his recurrent character must always lead to antibiotic prophylaxis. SN - 0041-4131 UR - https://www.unboundmedicine.com/medline/citation/12703126/[Erysipelas_after_breast_cancer_treatment]_ L2 - http://www.diseaseinfosearch.org/result/960 DB - PRIME DP - Unbound Medicine ER -